Splice-disrupt genomic variants in prostate cancer: Association of some
splice-disrupt variants with advanced prostate cancer
Abstract
Precise pre-mRNA splicing is vital for appropriate protein translation
where splice-disrupt variants may change the structure of transcripts
and their encoded proteins, resulting in a complete loss of function or
acquiring a new function. Splice-disrupt genomic variants are one of the
causes of cancer-causing errors in gene expression. Little is known
about splice-disrupt genomic variants. Here, pattern of splice-disrupt
variants in different types of prostate cancer was investigated using
huge deposited genomic variants in prostate cancer (21,842,764
variants). HLA-A, MSR1, and EGFR had the highest allele frequency of
splice-disrupt variation in prostate cancer, castration-resistant
prostate cancer, familial prostate cancer, and metastatic
castration-resistant, respectively. Intron, followed by CDs and 3’UTR
were enriched with the splice-disrupt mutations. Some splice-disrupt
variants, on CDs of NCOR2, PTPRC, and CRP that were solely present in
advanced metastatic castration-resistant prostate cancer. Damaging
splice-disrupt variants were identified based on PolyPhen, SIFT, and
GERP++ scores as well as clinical significance. Functional annotation of
damaging splice-disrupt variants highlighted important cancer-associated
functions including endocrine resistance, lipid metabolic process,
steroid metabolic process, regulation of mitotic cell cycle, and
regulation of metabolic process. This is the first study that profiles
the splice-disrupt genomic variants and their target genes in prostate
cancer.